Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (23) , 115815
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTCancer Cell, 2017
- Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)Journal of Medicinal Chemistry, 2016
- Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancyJournal of Experimental Medicine, 2015
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Genetic aberrations of signaling pathways in lymphomagenesis: Revelations from next generation sequencing studiesSeminars in Cancer Biology, 2013
- Strategies for a comprehensive understanding of metabolism by aldehyde oxidaseExpert Opinion on Drug Metabolism & Toxicology, 2012
- Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsACS Medicinal Chemistry Letters, 2011
- Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug DiscoveryJournal of Medicinal Chemistry, 2010
- Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in VivoDrug Metabolism and Disposition, 2007
- Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weightEuropean Journal of Pharmaceutical Sciences, 1998